Topic has been suspended
Status Suspended
Process TAG
ID number 2711


Key events during the development of the guidance:

Date Update
14 May 2020 Suspended, Topic has been suspended
14 May 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.
10 January 2020 In progress, Referred October 28 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance